Clinical trial
CART-19 Cells For Patients With Relapsed or Refractory B-cell Lymphoma
NCT03391726 is registered in ClinicalTrials.gov with Fujian Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CART-19 Cells For Patients With Relapsed or Refractory B-cell Lymphoma
- Lead sponsor
- Fujian Medical University
- Phase
- Phase 2/3
- Overall status
- Unknown status
- Start date
- January 1, 2016
- Completion date
- December 31, 2020
- Enrollment
- 20 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed or refractory b-cell lymphoma